This landmark study is the first-ever side-by-side comparison of 171 antibodies against Ebola virus.
A one-two punch of powerful antibodies may be the best way to stop Ebola virus, reports an international team of scientists in the journal Cell. Their findings suggest new therapies should disable Ebola virus’s infection machinery and spark the patient’s immune system to call in reinforcements.
“This study presents results from an unprecedented international collaboration and demonstrates how 43 previously competing labs can together accelerate therapeutics and vaccine design,” says Erica Ollmann Saphire, PhD, professor at Scripps Research and director of the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC).
From 2013–2016, West Africa faced the deadliest Ebola outbreak the world has ever seen. By the time the outbreak was declared over, 11,325 people had died. The VIC is an international group of the world’s leading virologists, immunologists, systems biologists and structural biologists working to stop an outbreak on that scale from ever striking again.
The VIC researchers aim to understand which Ebola-fighting antibodies are best—and why. The hope is that the most effective antibodies can be combined in a therapeutic “cocktail.” Unlike an Ebola vaccine, these cocktails could be given to those already infected, which is important for stopping a disease that tends to emerge unexpectedly in remote locations.
Ollmann Saphire and her colleagues in the VIC have published more than 40 studies in just the last five years. This landmark study is the first-ever side-by-side comparison of 171 antibodies against Ebola virus and other related viruses, known as filoviruses. All antibodies in the panel were donated by different labs around the world, and many had not been previously characterized in such extensive detail.
“Through the VIC, we could test a larger pool of antibodies in parallel, which increased the potential to detect statistically significant relationships between antibody features and protection,” says Saphire. “We used this global pool of antibodies to evaluate, and streamline, the research pipeline itself.”
In addition to identifying links between antibody target locations and activity, VIC researchers tested this huge pool of antibodies to reveal which antibodies “neutralized” the virus, why neutralization assays so often disagree, and whether or not neutralization in test tubes adequately predicted how well these antibodies would protect live animals from Ebola virus infection. Unexpectedly, neutralization alone was not always associated with the protective ability of an antibody.
Notably, the scientists found nine antibodies that protected mice from infection without neutralizing the virus in test tubes. These antibodies likely fight infection by interacting with an infected person’s immune system, helping orchestrate a better immune response to the virus.
This “immune effector” activity is featured in the team’s companion study published simultaneously in Cell Host & Microbe. “The ability to evoke an immune response will likely represent a new avenue of study for therapeutic antibodies for Ebola virus infection,” says Sharon Schendel, project manager for the VIC and science writer in the Saphire lab.
From the large body of results, VIC member and Scripps Research faculty member Kristian Andersen, PhD, and his graduate student Karthik Gangavarapu developed a network describing how each antibody feature correlates to protection, which can serve as a guide to predict whether newly identified antibodies will have therapeutic value. Saphire says the next steps for the VIC are to further test promising antibody cocktails in non-human primates. The team will also pursue engineering of antibodies that carry signature features to better drive immune system response.
The Latest on: Ebola
via Google News
The Latest on: Ebola
- How the coronavirus compares with SARS, ebola and other deadly viruseson January 31, 2020 at 2:30 pm
outbreak in China has stricken more than 7,800 people and killed 170 since its discovery in late December. The spread has been so quick that on Thursday, The World Health Organization declared it a ...
- Gilead working with China to test Ebola drug as new coronavirus treatmenton January 31, 2020 at 11:09 am
Gilead Sciences Inc ( GILD.O) said on Friday it provided its experimental Ebola therapy for use in a small number of patients with the coronavirus that has killed over 200 so far in China and is ...
- How the new coronavirus compares with SARS, ebola and other deadly viruseson January 31, 2020 at 10:10 am
Yet, despite the numbers and alarm, the virus pales in comparison to the impact of the ebola virus — and even more so — influenza. The latter killed more than 61,000 people in the U.S. alone during ...
- Responding to the coronavirus threat using lessons learned from Ebolaon January 30, 2020 at 2:23 pm
In 2014, when Ebola appeared to threaten the United States, calls for restricting travel, including limiting visas to possible travelers from infected areas, were fortunately never implemented. Now, ...
- Responding To The Coronavirus: Lessons Learned From The Fight Against Ebolaon January 29, 2020 at 1:08 pm
The coronavirus is not the first global virus to sow seeds of panic and uncertainty, but we have the tools and experience to address this crisis head-on—we’ve done it before.
- US learned from Ebola but is 'nowhere near as prepared' as needed if coronavirus outbreak happened hereon January 29, 2020 at 9:38 am
At the height of the Ebola epidemic in West Africa five years ago, CDC officials faced what seemed like an impossible request: Could U.S. airports screen passengers for the deadly virus when they ...
- Coronavirus Is No Ebola, and That Presents a Different Problemon January 29, 2020 at 8:53 am
The mild nature of the infection has experts worried it will spread far, and fast. Ebola kills half of the people who get it. China’s last worrying viral outbreak, SARS, killed 10%. The new ...
- FDA warns Purell to stop claiming hand sanitizers help kill the flu, Ebola and MRSAon January 28, 2020 at 5:36 pm
The U.S. Food and Drug Administration fired off a warning letter to the parent company of Purell, Gojo Industries, over the hand sanitizers’ health claims — mainly, that using Purell Healthcare ...
- F.D.A. Warns Purell to Stop Claiming It Can Prevent Ebola or Fluon January 28, 2020 at 3:24 pm
The Food and Drug Administration told the maker of Purell hand sanitizers to discontinue marketing campaigns that the agency complained also included claims for avoiding illness from other viruses.
via Bing News